secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001104659-24-045283
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health shareholders approve reverse split authorization; Nasdaq extends compliance deadline to Aug 13, 2024
--------------------------------------------------------------------------------

- Stockholders approved all four proposals at April 9 special meeting, including reverse split authorization up to 1-for-150.
- Company does not intend to implement reverse split at this time but seeks flexibility to maintain Nasdaq listing.
- Nasdaq granted extension until August 13, 2024 to regain $1 minimum bid price compliance.
- Phase 3 OnTarget trial top-line results for crofelemer in cancer therapy-related diarrhea are forthcoming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465924045283/0001104659-24-045283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465924045283/tm2411445d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-045283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer